I believe one way to go about it is to target the key enzymes that regulate essential pathways in bacteria and also DNA and protein synthesis machinery. Though easier said it will not be an easy journey in pursuit of treatment. But it is worth investigating .

In the short term The Detect and Protect Against Antibiotic Resistance Initiative (developed by CDC) provides a good starting point.

There are 4 core areas:

1. Detect and track patterns of antibiotic resistance.

2. Respond to outbreaks involving antibiotic-resistant bacteria.

3. Prevent infections from occurring and resistant bacteria from spreading.

4. Discover new antibiotics and new diagnostic tests for resistant bacteria.

Development of new antimcrobial agents, though appealing, is only a small part of global fight against resistant bacteria. I think it is more important to use better antibiótics we have today, improving antibiotic stewardship, and to prevent spread of resistant bacteria. This way we can gain time for the development of new drugs. We have the real problem now, And new therapeutic targets would need a long time to develop.

I think a possible way is to use combination of drugs. Combination of antibiotics is actually used clinically and achieves some success. One reason might be that the possibility is low for one bacteria to carry multiple resistance to antibiotics with different mode of actions. But even this is not good enough because bacteria will eventually get multiple resistance. A better way is to combine antibiotics with a drug that targets resistance genes. For example, the resistance to penicillin-like antibiotics includes the production of beta-lactamase. If we use beta-lactamase inhibitors together with the traditional antibiotics, we will be able to kill the resistant bacteria. But this is still not perfect. Bacteria can develop new beta-lactamases. So we still need to discover new inhibitors. We need to keep looking for some other resistance gene targets and find new drugs that can be used together with antibiotics.  

In my opinion, out of the antibiotics the catalysis/photocatalysis could be an alternative. I invite you to take a look to some  publications of our group.

http://www.enviscope.com/science/des-films-antibacteriens-revolutionnaires-imagines-a-lepfl/15060

http://aem.asm.org/content/early/2012/09/10/AEM.02266-12

Article Growth of TiO2/Cu films by HiPIMS for accelerated bacterial ...

using Clavulanic acid in the preparation of antimicrobial can show highest efficacy against resistant pathogen e.g. Amoxicillin + Clavulanic Acid, Cefuroxime + Clavulanic Acid.

Dear Daniel Deng,

It is nice to see your query on such a hot topic and one of the greatest worry.

Besides the cocktails of various antibiotics and/or bacteriostatic compounds, it is now becoming important to disrupt biofilms. Thus Quorum sensing inhibitors (QSIs) are adding up to our arsenal against bacterial biofilm forming pathogens. It has been argued that to achieve maximum benefit of our research, one should use a combination of antibiotics/QSIs and other membrane protein inhibitors. If used carefully, this approach could help to minimize the risk of getting resistant bacteria. 

Field trials of such compounds is going on worldwide.

You may go through the links below.

http://www.sciencedirect.com/science/article/pii/S0734975012001851

http://www.sciencedirect.com/science/article/pii/S0734975013001419

Biggest threats are XDRTB, Carbapenemase producing Gram Negative bacteria and even Tigecycline resistant ones.

There have been deaths because of such resistant microbes and we have no answer. 

Whether we agree or not its the result of misuse and abuse of antibiotics.

Bacteria are winning the race in overcoming the newer antimicrobials.

May be we are left with the choice of trying out bactriophages and plant extracts.

Governments being optimistic, throughout the world have been funding for research on plant extracts as antimicrobials.

You can read latest literature from authors

Ashima Kushwaha Bhardwaj*, Kittappa Vinothkumar, Neha Rajpara, Priyabrata Mohanty and Braj Mohan Ram Narayan Singh Kutar. Therapeutic Limitations Due to Antibiotic Drug Resistance: Road to Alternate Therapies. Frontiers in Anti-Infective Drug Discovery (e. book), Vol. 3, 2014 (In Press). Bentham Science Publishers. Editors: Atta-ur-Rahman and M. Iqbal Choudhary.

Ashima Kushwaha Bhardwaj. Multi-drug resistance in vibrios - Never underestimate bacteria. Advances in Biotechnology and Allied Areas. 2014 (In Press) I. K. International Publishing House Pvt. Ltd., Delhi. Editors: Neelu Nawani, Madhukar Khetmalas, Ashok Pandey, P. M Razdan and K. B Powar.

Bhardwaj AK, Vinothkumar K, Rajpara N. Bacterial quorum sensing inhibitors: Attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat Antiinfect Drug Discov. 2013;8:68-83.

Bhardwaj A K, Mohanty P. (2012) Bacterial Efflux Pumps Involved in Multidrug Resistance and their Inhibitors: Rejuvinating the Antimicrobial Chemotherapy. Recent Pat Antiinfect Drug Discov. 7, 73-89 

There was an extensive research carried out on using copper alloys in hospital environments as the replacement of stainless steel. It was shown that this approach was a good solution to eliminate antbiotic-resistant strains of bacteria. Please check the following link

http://copperalliance.org.uk/copper-and-its-alloys/alloys/coppers

There is a lot of research about silver. Silver as a coating agent on on side (like for urinary catheters),nowadays it s even used in deodorants. The second way of usind silver is colloidal silver.

Colloidal silver is silver in smallest particles (it is not ions, but metal particles , "Ag"). It is known to fight bacterial infections for quite some time now and can be taken orally also.

There are also publications about combining "normal" antibiotics with colloidal silver.

Two-component histidine kinase receptors are being re-visited as drug targets.

www.ScienceTranslationalMedicine.org 18 September 2013 Vol 5 Issue 203 203ps12

All Signals Lost Kaelyn E. Wilke1 and Erin E. Carlson1,2* Inhibitors of bacterial histidine kinases that globally deactivate bacterial signaling may ofer a new ofensive against antibiotic resistance.

New antibacterial targets are vital to combat the alarming rate of resistance de- velopment to available drugs. Histidine ki- nase (HK) proteins are the primary means by which microbes sense and respond to their environment. Tus, broad-spectrum HK inhibitors should render bacteria largely blinded to their surroundings, re- sulting in decreased viability, pathogenic- ity, and virulence.

Bacteriophage therapy, MDT Therapy, herbal therapy, Cowpathy, Si-RNA therapy, cytokine therapy, panchgavya therapy etc can be used for treating drug resistant bacteria. 

as much as possible, always try to use anti microbial drugs after culture and sensitivity test results. If you provide broad spectrum drugs, of course, the problem will spread fast. Thus, if it is difficult to have culture and sensitivity test, better to update medical persons(doctores...) about the drugs which are already resistant to specific bacterial species, and make them strongly follow it.As well, better to have a sort of journal club in helath instittion, for the regular updates.

Follow alternative therapies and basic principles to avoid its emergence

Hi...............

                    If your question is about how to target drug-resistant bacteria, then u can think about antisense oligonucleotides.

Certainly bacteriophage therapy is one approach. The Russians did a lot of work on this area back in the 30's prior to the advent of sulpha drugs and the penicillin derivatives taking over

Follow appropriate drug sensitivity testing and prescribe best drug - it will work, or if not then follow alternative and novel as well as complementary therapeutic regimens like phages, herbs, avian egg antibodies, cytokines etc 

Bacteriophage is a best option to treat a multiple drug resistant bacteria you want the further recommendation about the phage therapy than contact me 

Hi there,

has been some success in using avirulent strains as inoculants to induce immunity and also competition for toxin binding sites. This has certainly worked in agriculture (Agrobacterium tumefaciens) but has also been reported in clinical settings. I think S.pneumoniae avirulent strains have been used as inoculants to prevent otitis media. Of course this is a preventative approach rather than a treatment - but to my mind prevention is still better than cure.

cheers,

Richard

Hi

Efflux pump inhibitors (EPIs) are promising therapeutic agents, as they should restore the activityof standard antibiotics. The efflux pump inhibitor-antibiotic combination is

expected to increase the intracellular concentration of antibiotics that are expelled by efflux pumps, decrease the intrinsic bacterial resistance to antibiotics, reverse the acquired resistance associated with efflux pumps overexpression, and reduce

the frequency of the emergence of resistant mutant strains.